Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations

(2011) Angelika Banzhoff et al.   Human vaccines & immunotherapeutics

Hemagglutination Inhibition Antibody Titers as a Correlate of Protection for Inactivated Influenza Vaccines in Children

(2011) Steven Black et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis

(2011) F. Alghisi et al.   THORAX

Immunogenicity and safety of inactivated influenza vaccines in primed populations: A systematic literature review and meta-analysis

(2011) W.E.P. Beyer et al.   VACCINE

Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents

(2011) Susanna Esposito et al.   VACCINE

Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals

(2010) Anna Kajaste-Rudnitski et al.   AIDS

MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk

(2010) Paolo Durando et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

MF59™ as a vaccine adjuvant: a review of safety and immunogenicity

(2010) Hana El Sahly   Expert Review of Vaccines

Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study

(2010) Nabihah Sachedina et al.   LANCET

Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study

(2010) Elizabeth Miller et al.   LANCET

An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients

(2010) S. Esposito et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to

(2010) Chi-Eun Oh et al.   VACCINE

Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with β-thalassemia major

(2010) Susanna Esposito et al.   VACCINE

Strategies for Pandemic and Seasonal Influenza Vaccination of Schoolchildren in the United States

(2009) N. E. Basta et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials

(2009) Eric Plennevaux et al.   LANCET

Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine

(2009) Tristan W. Clark et al.   NEW ENGLAND JOURNAL OF MEDICINE

Enhanced Immunogenicity of Seasonal Influenza Vaccines in Young Children Using MF59 Adjuvant

(2009) Timo Vesikari et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

The Transmissibility and Control of Pandemic Influenza A (H1N1) Virus

(2009) Y. Yang et al.   SCIENCE

Optimizing Influenza Vaccine Distribution

(2009) J. Medlock et al.   SCIENCE

MF59-adjuvanted versus non-adjuvanted influenza vaccines: Integrated analysis from a large safety database

(2009) Michele Pellegrini et al.   VACCINE

Exposure to MF59-adjuvanted influenza vaccines during pregnancy—A retrospective analysis

(2009) Theodore Tsai et al.   VACCINE

MF59® -adjuvanted vaccines for seasonal and pandemic influenza prophylaxis

(2008) Angelika Banzhoff et al.   Influenza and Other Respiratory Viruses

Safety of MF59™ adjuvant

(2008) Viola Schultze et al.   VACCINE